![](https://ltrpharma.com/wp-content/uploads/2024/07/Ausbiz.png)
Ausbiz | Interview with Lee Rodne
Following this week’s announcement of a successful $10.5M capital raise, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with ausbiz about future plans for the commercial
![](https://ltrpharma.com/wp-content/uploads/2024/07/Stockhead-Shortz.png)
Stockhead Shortz | Interview with Lee Rodne
In an interview with Stockhead‘s Sarah Hughan, LTR Pharma Executive Chairman Lee Rodne spoke of the Company’s successful $10.5 million capital raise, and how the
![](https://ltrpharma.com/wp-content/uploads/2024/07/The-Australian-.png)
The Australian Business Review | LTP Pharma raises $10.5m to advance erectile dysfunction treatment SPONTAN
LTR Pharma’s A$10.5 million share placement has been featured in The Australian Business Review. Click to read the article.
![](https://ltrpharma.com/wp-content/uploads/2024/07/Cap-Raise.png)
LTR Pharma completes A$10.5 million placement to expedite commercialisation of SPONTAN®
LTR Pharma has today announced that it has successfully completed a A$10.5 million Share Placement to sophisticated and new institutional investors to expedite the commercialisation
![](https://ltrpharma.com/wp-content/uploads/2024/07/Video-4.png)
Conversation Series | Treatment Innovation for ED – Introduction to SPONTAN®
The fourth instalment of the LTR Pharma Conversation Series is now live. This week, Professor Chung shares insights into nasal delivery technology and why it
![](https://ltrpharma.com/wp-content/uploads/2024/06/Courier-Mail-1-768x768.png)
The Courier Mail | LTR hard sell not required
Following last week’s announcement of positive results from our SPONTAN® pivotal bioequivalence clinical study, LTR Pharma was featured in The Courier Mail’s City Beat by